- Home
- QXO vs MDGL Comparison
QXO vs MDGL Comparison
Compare QXO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | MDGL |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | 7794 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 12.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | QXO | MDGL |
|---|---|---|
| Price | $20.30 | $518.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $32.85 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 15.0M | 261.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $70.27 | $58.39 |
| Revenue Next Year | $38.75 | $48.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.09 | $265.00 |
| 52 Week High | $27.61 | $615.00 |
Technical Indicators
Market Signals| Indicator | QXO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 53.02 |
| Support Level | $18.48 | $503.93 |
| Resistance Level | $20.54 | $539.17 |
| Average True Range (ATR) | 1.19 | 15.73 |
| MACD | -0.30 | -3.53 |
| Stochastic Oscillator | 20.40 | 38.62 |
Price Performance
Historical ComparisonAbout QXO QXO Inc.
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.